PeptideCompareHome / Peptide Database / Cagrilintide
AMYLIN ANALOGUE — WEIGHT
Cagrilintide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, designed for once-weekly dosing. In combination with semaglutide (CagriSema), it has shown up to 22% weight loss in Phase 3 trials.
Available strengths
10mg
1 of 1 rows in stock
How to use it: compare suppliers below side by side on price and whether a COA is on file — those two checks are the fastest way to spot a good deal. All COAs can be verified directly on each supplier's own website.
Prices manually checked and updated monthly — source: publicly available supplier data. No affiliate links, no paid placement.
Cagrilintide
Mechanism, evidence level, EU status and COA guidance per compound. No dosages, no protocols — that belongs with a doctor.